{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:45:46Z","timestamp":1794278746068,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obtaining an imaging diagnosis of various hepatobiliary and pancreatic disorders caused by certain drugs can often be challenging. Familiarity with these conditions may improve diagnostic accuracy and patient management. This review aimed to describe the imaging findings of drug-associated hepatobiliary and pancreatic disorders and identify suggestions for obtaining a correct diagnosis. We focused on relatively common disorders or those that can present with characteristic imaging findings, such as drug-induced acute hepatitis, sinusoidal obstruction syndrome, focal nodular hyperplasia-like lesions, hepatocellular adenoma, pseudocirrhosis, chemotherapy-associated steatohepatitis, amiodarone deposition in the liver, secondary iron overload, drug-induced pancreatitis, pancreatic enlargement after epoprostenol therapy, ceftriaxone-associated gallbladder pseudolithiasis, immune-related adverse events, and methotrexate-associated lymphoproliferative disorders.<\/jats:p>","DOI":"10.1007\/s11604-023-01505-z","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T04:10:09Z","timestamp":1699243809000},"page":"235-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Key CT and MRI findings of drug-associated hepatobiliary and pancreatic disorders"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-8472","authenticated-orcid":false,"given":"Shintaro","family":"Ichikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"1505_CR1","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222\u201361.","journal-title":"J Hepatol"},{"key":"1505_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","volume":"394","author":"RT Stravitz","year":"2019","unstructured":"Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019;394:869\u201381.","journal-title":"Lancet"},{"key":"1505_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/liv.13931","volume":"39","author":"A Hassan","year":"2019","unstructured":"Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int. 2019;39:31\u201341.","journal-title":"Liver Int"},{"key":"1505_CR4","first-page":"3312","volume":"44","author":"F Vernuccio","year":"2019","unstructured":"Vernuccio F, Dioguardi Burgio M, Barbiera F, Cusm\u00e0 S, Badalamenti G, Midiri M, et al. CT and MR imaging of chemotherapy-induced hepatopathy. AbdomRadiol (NY). 2019;44:3312\u201324.","journal-title":"AbdomRadiol (NY)"},{"key":"1505_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-0041-1729972","volume":"41","author":"F Bessone","year":"2021","unstructured":"Bessone F, Hern\u00e1ndez N, Tanno M, Roma MG. Drug-induced vanishing bile duct syndrome: from pathogenesis to diagnosis and therapeutics. Semin Liver Dis. 2021;41:331\u201348.","journal-title":"Semin Liver Dis"},{"key":"1505_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clinre.2020.03.019","volume":"44","author":"V de L\u00e9dinghen","year":"2020","unstructured":"de L\u00e9dinghen V, Villate A, Robin M, Decraecker M, Valla D, Hillaire S, et al. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2020;44:480\u20135.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1505_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12328-012-0333-2","volume":"5","author":"H Toi","year":"2012","unstructured":"Toi H, Miura Y, Shibasaki S, Chisaka K, Goto M, Tsuda I, et al. Hepatic sinusoidal obstruction associated with S-1 plus cisplatin chemotherapy for highly advanced gastric cancer with paraaortic lymph node metastases: report of a case. Clin J Gastroenterol. 2012;5:341\u20136.","journal-title":"Clin J Gastroenterol"},{"key":"1505_CR8","first-page":"864","volume":"22","author":"NY Shin","year":"2012","unstructured":"Shin NY, Kim MJ, Lim JS, Park MS, Chung YE, Choi JY, et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. EurRadiol. 2012;22:864\u201371.","journal-title":"EurRadiol"},{"key":"1505_CR9","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s00261-015-0503-z","volume":"40","author":"N Yoneda","year":"2015","unstructured":"Yoneda N, Matsui O, Ikeno H, Inoue D, Yoshida K, Kitao A, et al. Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging. 2015;40:3099\u2013103.","journal-title":"Abdom Imaging"},{"key":"1505_CR10","doi-asserted-by":"publisher","first-page":"69024","DOI":"10.18632\/oncotarget.11816","volume":"7","author":"H Kim","year":"2016","unstructured":"Kim H, Baek SE, Moon J, Roh YH, Lee N, Cho A. Increased hepatic FDG uptake on PET\/CT in hepatic sinusoidal obstructive syndrome. Oncotarget. 2016;7:69024\u201331.","journal-title":"Oncotarget"},{"issue":"4","key":"1505_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/diagnostics12040867","volume":"12","author":"F Donati","year":"2022","unstructured":"Donati F, Cioni D, Guarino S, Mazzeo ML, Neri E, Boraschi P. Chemotherapy-induced liver injury in patients with colorectal liver metastases: findings from MR imaging. Diagnostics (Basel). 2022;12(4):867.","journal-title":"Diagnostics (Basel)."},{"key":"1505_CR12","first-page":"2321","volume":"43","author":"E \u00dcnal","year":"2018","unstructured":"\u00dcnal E, Karaosmano\u011flu AD, Ozmen MN, Akata D, Karcaaltincaba M. Hepatobiliary phase liver MR imaging findings after oxaliplatin-based chemotherapy in cancer patients. AbdomRadiol (NY). 2018;43:2321\u20138.","journal-title":"AbdomRadiol (NY)"},{"key":"1505_CR13","first-page":"370","volume":"26","author":"HN \u00d6zcan","year":"2020","unstructured":"\u00d6zcan HN, Kar\u00e7aalt\u0131ncaba M, Seber T, Yal\u00e7\u0131n B, O\u011fuz B, Aky\u00fcz C, et al. Hepatocyte-specific contrast-enhanced MRI findings of focal nodular hyperplasia-like nodules in the liver following chemotherapy in pediatric cancer patients. DiagnIntervRadiol. 2020;26:370\u20136.","journal-title":"DiagnIntervRadiol"},{"key":"1505_CR14","unstructured":"Shreenath AP, Kahloon A. Hepatic Adenoma. 2023 Jan 16. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513264\/."},{"key":"1505_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.5858\/arpa.2013-0183-RA","volume":"138","author":"S Dhingra","year":"2014","unstructured":"Dhingra S, Fiel MI. Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics. Arch Pathol Lab Med. 2014;138:1090\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"1505_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/liv.14074","volume":"39","author":"HN \u00d6zcan","year":"2019","unstructured":"\u00d6zcan HN, Kar\u00e7aalt\u0131ncaba M, Seber T, Yal\u00e7\u0131n B, O\u011fuz B, Aky\u00fcz C, et al. The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: a retrospective cohort study. Liver Int. 2019;39:905\u201313.","journal-title":"Liver Int"},{"key":"1505_CR17","first-page":"2436","volume":"29","author":"S Bise","year":"2019","unstructured":"Bise S, Frulio N, Hocquelet A, Alberti N, Blanc JF, Laurent C, et al. New MRI features improve subtype classification of hepatocellular adenoma. EurRadiol. 2019;29:2436\u201347.","journal-title":"EurRadiol"},{"key":"1505_CR18","first-page":"3497","volume":"30","author":"TA Auer","year":"2020","unstructured":"Auer TA, Fehrenbach U, Grieser C, Penzkofer T, Geisel D, Schmelzle M, et al. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation? EurRadiol. 2020;30:3497\u2013506.","journal-title":"EurRadiol."},{"key":"1505_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679163","volume":"11","author":"D Gopalakrishnan","year":"2021","unstructured":"Gopalakrishnan D, Shajihan A, Purysko AS, Abraham J. Pseudocirrhosis in breast cancer\u2014experience from an academic cancer center. Front Oncol. 2021;11: 679163.","journal-title":"Front Oncol"},{"key":"1505_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-019-05311-y","volume":"177","author":"C Oliai","year":"2019","unstructured":"Oliai C, Douek ML, Rhoane C, Bhutada A, Ge PS, Runyon BA, et al. Clinical features of pseudocirrhosis in metastatic breast cancer. Breast Cancer Res Treat. 2019;177:409\u201317.","journal-title":"Breast Cancer Res Treat"},{"key":"1505_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.aohep.2019.11.012","volume":"19","author":"L Meunier","year":"2020","unstructured":"Meunier L, Larrey D. Chemotherapy-associated steatohepatitis. Ann Hepatol. 2020;19:597\u2013601.","journal-title":"Ann Hepatol"},{"key":"1505_CR22","first-page":"228","volume":"6","author":"M Babatin","year":"2008","unstructured":"Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. CurrVascPharmacol. 2008;6:228\u201336.","journal-title":"CurrVascPharmacol"},{"key":"1505_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11604-018-0733-4","volume":"36","author":"M Matsuda","year":"2018","unstructured":"Matsuda M, Otaka A, Tozawa T, Asano T, Ishiyama K, Hashimoto M. Analysis of computed tomography density of liver before and after amiodarone administration. Jpn J Radiol. 2018;36:340\u20134.","journal-title":"Jpn J Radiol"},{"key":"1505_CR24","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.12998\/wjcc.v8.i20.4958","volume":"8","author":"HJ Lv","year":"2020","unstructured":"Lv HJ, Zhao HW. Amiodarone-induced hepatotoxicity\u2014quantitative measurement of iodine density in the liver using dual-energy computed tomography: three case reports. World J Clin Cases. 2020;8:4958\u201365.","journal-title":"World J Clin Cases"},{"key":"1505_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13256-018-1629-8","volume":"12","author":"T Tsuda","year":"2018","unstructured":"Tsuda T, Tada H, Tanaka Y, Nishida N, Yoshida T, Sawada T, et al. Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. J Med Case Rep. 2018;12:95.","journal-title":"J Med Case Rep"},{"key":"1505_CR26","unstructured":"Rasel M, Mahboobi SK. Transfusion iron overload. StatPearls; 2023. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32965817."},{"issue":"21","key":"1505_CR27","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.3390\/nu14214480","volume":"14","author":"D Berlana","year":"2022","unstructured":"Berlana D. Parenteral nutrition overview. Nutrients. 2022;14(21):4480.","journal-title":"Nutrients"},{"key":"1505_CR28","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221856","volume":"307","author":"SB Reeder","year":"2023","unstructured":"Reeder SB, Yokoo T, Fran\u00e7a M, Hernando D, Alberich-Bayarri \u00c1, Al\u00fastiza JM, et al. Quantification of liver iron overload with MRI: review and guidelines from the ESGAR and SAR. Radiology. 2023;307: e221856.","journal-title":"Radiology"},{"key":"1505_CR29","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/hep4.2012","volume":"6","author":"CC Hsu","year":"2022","unstructured":"Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. Iron overload disorders. Hepatol Commun. 2022;6:1842\u201354.","journal-title":"Hepatol Commun"},{"key":"1505_CR30","first-page":"45","volume":"15","author":"MR Jones","year":"2015","unstructured":"Jones MR, Hall OM, Kaye AM, Kaye AD. Drug-induced acute pancreatitis: a review. Ochsner J. 2015;15:45\u201351.","journal-title":"Ochsner J"},{"key":"1505_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajg.2019.11.005","volume":"20","author":"J Zheng","year":"2019","unstructured":"Zheng J, Yang QJ, Dang FT, Yang J. Drug-induced pancreatitis: an update. Arab J Gastroenterol. 2019;20:183\u20138.","journal-title":"Arab J Gastroenterol"},{"key":"1505_CR32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.cgh.2006.11.023","volume":"5","author":"N Badalov","year":"2007","unstructured":"Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5:648\u201361.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1505_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/17512433.2021.1929925","volume":"14","author":"MJ Cristo Ropero","year":"2021","unstructured":"Cristo Ropero MJ, Cruz-Utrilla A, Escribano-Subias MP. Epoprostenol for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol. 2021;14:1005\u201313.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1505_CR34","first-page":"1948","volume":"47","author":"Y Someya","year":"2022","unstructured":"Someya Y, Koyasu S, Ohnishi Y, Ohno T, Shimizu H, Isoda H, et al. Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report. AbdomRadiol (NY). 2022;47:1948\u201353.","journal-title":"AbdomRadiol (NY)"},{"key":"1505_CR35","first-page":"623","volume":"222","author":"T Homma","year":"1982","unstructured":"Homma T, Malik KU. Effect of prostaglandins on pancreatic circulation in anesthetized dogs. J Pharmacol Exp Ther. 1982;222:623\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"1505_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/fcp.12577","volume":"35","author":"L Cuzzolin","year":"2021","unstructured":"Cuzzolin L, Oggiano AM, Clemente MG, Locci C, Antonucci L, Antonucci R. Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough? Fundam Clin Pharmacol. 2021;35:40\u201352.","journal-title":"Fundam Clin Pharmacol"},{"key":"1505_CR37","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.2169\/internalmedicine.7611-21","volume":"60","author":"K Hotta","year":"2021","unstructured":"Hotta K, Hashimura N, Takatsuka M, Matsuyama T, Nakagawa K, Yabusako T, et al. Ceftriaxone-associated pseudolithiasis in elderly people: frequency and risk factors. Intern Med. 2021;60:3857\u201364.","journal-title":"Intern Med"},{"key":"1505_CR38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s11604-019-00893-5","volume":"37","author":"R Yoshida","year":"2019","unstructured":"Yoshida R, Yoshizako T, Katsube T, Kitagaki H. Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults. Jpn J Radiol. 2019;37:826\u201331.","journal-title":"Jpn J Radiol"},{"key":"1505_CR39","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.","journal-title":"Front Immunol"},{"key":"1505_CR40","doi-asserted-by":"publisher","first-page":"20200663","DOI":"10.1259\/bjr.20200663","volume":"94","author":"MA Anderson","year":"2021","unstructured":"Anderson MA, Kurra V, Bradley W, Kilcoyne A, Mojtahed A, Lee SI. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. Br J Radiol. 2021;94:20200663.","journal-title":"Br J Radiol"},{"key":"1505_CR41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","volume":"72","author":"B Sangro","year":"2020","unstructured":"Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72:320\u201341.","journal-title":"J Hepatol"},{"key":"1505_CR42","unstructured":"Justiz Vaillant AA, Stang CM. Lymphoproliferative disorders. StatPearls; 2022. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30725847."},{"key":"1505_CR43","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2169\/internalmedicine.4787-20","volume":"59","author":"M Tsuruoka","year":"2020","unstructured":"Tsuruoka M, Inoue J, Kakazu E, Ninomiya M, Iwata T, Sano A, et al. Methotrexate-associated lymphoproliferative disorder in the liver resembling hepatocellular carcinoma treated with transarterial chemoembolization. Intern Med. 2020;59:2255\u201360.","journal-title":"Intern Med"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-023-01505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-023-01505-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-023-01505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T04:52:22Z","timestamp":1709095942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-023-01505-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s11604-023-01505-z","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}